CapitalOne analyst Zegbah Jallah reiterated an Underweight rating and $35.00 price target on EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT)The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE